Ananda Pharma (STU:1FX) Shares Outstanding (EOP): 4,299.15 Mil (As of Jul. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Ananda Pharma Shares Outstanding (EOP)?

Ananda Pharma STU:1FX Shares Outstanding (EOP) is 4,299.15 Mil as of Jul. 2025. The stock has 5 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Ananda Pharma's shares outstanding for the quarter that ended in Jul. 2025 was 4,299.15 Mil.

Ananda Pharma's quarterly shares outstanding stayed the same from Jan. 2025 (4,299.15 Mil) to Jul. 2025 (4,299.15 Mil).

Ananda Pharma's annual shares outstanding increased from Jan. 2024 (2,878.03 Mil) to Jan. 2025 (4,299.15 Mil). It means Ananda Pharma issued new shares from Jan. 2024 to Jan. 2025 .


Ananda Pharma  (STU:1FX) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Ananda Pharma Shares Outstanding (EOP) Related Terms


Ananda Pharma Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Ananda Pharma's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ananda Pharma Shares Outstanding (EOP) Chart

Ananda Pharma Annual Data
Trend Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25
Shares Outstanding (EOP)
Get a 7-Day Free Trial 464.14 721.53 1,170.56 2,878.03 4,299.15

Ananda Pharma Semi-Annual Data
Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23 Jan24 Jul24 Jan25 Jul25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,873.85 2,878.03 4,256.29 4,299.15 4,299.15

STU:1FX vs ZTS, UTHR, VTRS: Shares Outstanding (EOP) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ananda Pharma's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ananda Pharma Shares Outstanding (EOP) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ananda Pharma's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Ananda Pharma's Shares Outstanding (EOP) falls into.



Ananda Pharma Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 4,299.15 Mil mean?
Ananda Pharma (STU:1FX) has a Shares Outstanding (EOP) of 4,299.15 Mil as of Jul. 2025. The total shares a company has outstanding, at period-end. View historical data on Ananda Pharma and its competitors.
Is Ananda Pharma's Shares Outstanding (EOP) too high?
Ananda Pharma's current Shares Outstanding (EOP) is 4,299.15 Mil.
How does Ananda Pharma's Shares Outstanding (EOP) compare to ZTS and UTHR?
Ananda Pharma's Shares Outstanding (EOP) of 4,299.15 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Ananda Pharma and its competitors. Ananda Pharma's current Shares Outstanding (EOP) is 4,299.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ananda Pharma stock overvalued right now?
Ananda Pharma (STU:1FX) has a current Shares Outstanding (EOP) of 4,299.15 Mil. The current Shares Outstanding (EOP) is 4,299.15 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Ananda Pharma (STU:1FX), the current Shares Outstanding (EOP) is 4,299.15 Mil as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ananda Pharma Business Description

Address 60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Ananda Pharma PLC is a UK-based biopharmaceutical company developing regulatory-approved, cannabidiol medicines to treat complex, chronic conditions, including endometriosis (funded by NHS Scotland) and chemotherapy-induced peripheral neuropathy (funded by NIHR).